远川投资评论·2025-06-18 07:00Core Viewpoint - The focus of investment has shifted from AI to innovative pharmaceuticals, with significant interest and funding directed towards the latter, as evidenced by attendance at recent strategy meetings and substantial capital inflows into the sector [1][4]. Group 1: Market Trends - Innovative pharmaceuticals have seen a surge in investment, with southbound funds increasing their holdings by 55.14 billion, three times more than new consumer sectors [4]. - The healthcare sector's share of Hong Kong stock trading volume has risen from less than 5% a year ago to 15% [4]. - The top ten public funds this year are dominated by innovative pharmaceutical funds, indicating a shift in market sentiment and investment strategies [4][5]. Group 2: Fund Manager Insights - Fund manager Zhou Sicong has noted a correlation between the performance of innovative pharmaceuticals and AI, suggesting that when one sector performs well, the other may not [2][3]. - Zhou has observed that TMT fund managers are increasingly involved in innovative pharmaceuticals, indicating a broader interest in the sector [3]. - The current market dynamics have led to a new generation of fund managers emerging as leaders in the innovative pharmaceutical space, while traditional managers have struggled [5][21]. Group 3: Investment Opportunities - The introduction of ADC (Antibody-Drug Conjugates) has proven the value of innovative pharmaceuticals, leading to significant licensing deals and collaborations with major global pharmaceutical companies [10][11]. - The potential for licensing out agreements is projected to account for nearly 30% of global sales in the coming years, highlighting a key growth area for innovative pharmaceuticals [11]. - The market is increasingly recognizing the strength of Chinese innovative pharmaceuticals, with a shift in how these assets are valued and perceived globally [12][21]. Group 4: Valuation and Market Sentiment - The traditional valuation methods for innovative pharmaceuticals are being challenged, with new metrics emerging that reflect the changing landscape of the industry [17][18]. - The current excitement around innovative pharmaceuticals is contrasted with previous market downturns, suggesting a more optimistic outlook for the sector moving forward [21][22]. - Despite concerns about potential bubbles in the market, there is a growing belief in the long-term potential of Chinese innovative pharmaceuticals to surpass their global counterparts [21][22].